The largest database of trusted experimental protocols

2 protocols using new born calf serum

1

Isolation and Culture of Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human umbilical vein endothelial cells (abbreviated as HUVECs) were isolated, cultured, and characterized as previously described [44 (link),45 (link)]. Cells were cultured on gelatin-coated dishes in cM199 (M199 medium supplemented with 20% heat-inactivated new born calf serum (both from Cambrex, Verviers, Belgium), 150 μg/mL crude endothelial cell growth factor (ECGF), 5 U/mL heparin, 100 IU/mL penicillin, and 100 μg/mL streptomycin) at 37 °C under 5% CO2/95% air atmosphere. Twenty-four hours prior to the experiments, the endothelial cell cultures were refreshed with a serum-reduced (10%) medium without crude endothelial cell growth factor. Cell viability, estimated by trypan blue exclusion, was greater than 95% before each experiment.
Human dermal microvascular endothelial cells (abbreviated as HMVEC-D or HMVECs) were purchased from Lonza (Lonza Walkersville, Inc., Walkersville, MD, USA) and cultured according to the supplier’s instructions. Briefly, cells were cultured in EGMTM-2MV (endothelial growth medium), containing basal medium supplemented with human epidermal growth factor (hEGF), vascular endothelial growth factor (VEGF), R3-insulin like growth factor-1 (R3-IGF-1), ascorbic acid, hydrocortisone, human fibroblast growth factor-beta (hFGF-β), fetal bovine serum (FBS), and gentamicin/amphotericin-β (GA) solution (Lonza, USA) at 37 °C under 5% CO2/95% air atmosphere.
+ Open protocol
+ Expand
2

HUVEC Culture and Gal-8 Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell culture. In the present study we used primary cultures of HUVECs that were isolated and expanded following published protocol (52) (link) and with respect to the Helsinki Declaration (53) (link) with an informed consent from donors. The study was approved by the Ethical committee of the Faculty of Pharmacy, Comenius University in Bratislava (06/2019). All in vitro experiments were performed using HUVECs at passage 2-3 isolated from 3 donors. Cells were cultured on gelatin-coated dishes in M199 supplemented with 20% heat-inactivated new born calf serum (both from Cambrex, Verviers, Belgium), 150 μg/ml crude endothelial cell growth factor (ECGF), 5 U/ml heparin, 100 IU/ml penicillin, and 100 μg/ml streptomycin (all from Invitrogen, Carlsbad, CA, USA) at 37˚C under 5% CO 2 / 95% air atmosphere. Twenty-four hours prior to the experiments the endothelial cell cultures were refreshed with Opti-MEM TM I Reduced Serum Medium (Thermo Fisher Scientific, Waltham, MA, USA). Cell viability, estimated by trypan blue exclusion, was higher than 95% before each experiment. As a positive control, 25 ng/ml of VEGF (R&D Systems, Minneapolis, MN, USA) (54) (link), was used in all experiments. Recombinant human Gal-8 (R&D Systems) was tested at the following concentrations: i) 0.004, ii) 0.02, iii) 0.1, iv) 0.5, and v) 1.0 μg/ml.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!